Peginterferon and ribavirin treatment for hepatitis C virus infection

查看全文 作　　者：Akihito [1]Tsubota;Kiyotaka [1]Fujise;Yoshihisa [1]Namiki;Norio [1]Tada

机构地区：[1]Institute of Clinical Medicine and Research, Jikei University School of Medicine

出　　处：《World Journal of Gastroenterology》索引2011年第17卷第4期,共14页

摘　　要：Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNα and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients. 关键词：丙型肝炎病毒治疗药物聚乙二醇化病毒感染利巴韦林干扰素修改方案结合疗法

相关文献

参考文献（120）
引证文献（16）
耦合文献（2）

参考文献(120)

引证文献(16)

耦合文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Peginterferon and ribavirin treatment for hepatitis C virus infection

参考文献(120)

引证文献(16)

耦合文献(2)

用户提示